{
    "cancer_info": {
        "cancer_name": "Immunotherapy-Related Toxicities (across multiple cancer types)"
    },
    "diagnosis_recommendations": {
        "examinations": [
            "ECG",
            "Troponin",
            "NT-proBNP",
            "TSH",
            "FT4",
            "Cortisol",
            "HbA1c",
            "O2 saturation",
            "Chest imaging",
            "Skin biopsy",
            "Liver biopsy",
            "Myocardium biopsy",
            "Autoantibodies (anti-desmoglein, AchR antibodies)",
            "Ferritin",
            "Cardiac MRI",
            "Chest CT",
            "Morning cortisol",
            "ACTH",
            "Testosterone",
            "Estrogen",
            "Renin",
            "Comprehensive Metabolic Panel",
            "Stool studies (C. difficile, pathogens)",
            "Fecal lactoferrin/calprotectin",
            "Abdominal/pelvic CT with contrast",
            "Colonoscopy",
            "ALT",
            "AST",
            "Alkaline phosphatase",
            "Bilirubin",
            "Viral serologies (HBV, HCV, HIV)",
            "Abdominal ultrasound/CT/MRI",
            "CBC",
            "Peripheral smear",
            "Reticulocyte count",
            "LDH",
            "Haptoglobin",
            "Direct antiglobulin test",
            "Bone marrow biopsy",
            "Acetylcholine receptor antibodies",
            "MRI brain/spine",
            "Lumbar puncture",
            "EMG",
            "Pulse oximetry",
            "Bronchoscopy with BAL",
            "IL-6 levels",
            "CRP",
            "Ferritin",
            "ICE score assessment",
            "Brain MRI",
            "CSF analysis",
            "Soluble CD25",
            "NK function tests"
        ]
    },
    "staging_treatment_plans": [
        {
            "staging_criteria": "Grade 1 (Mild)",
            "risk_group": "General",
            "treatment_plans": [
                {
                    "treatment_line": "First-line",
                    "patient_subgroup": "All patients",
                    "plan_name": "Monitoring",
                    "plan_details": "Continue immunotherapy with close monitoring",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Recommended"
                }
            ]
        },
        {
            "staging_criteria": "Grade 2 (Moderate)",
            "risk_group": "General",
            "treatment_plans": [
                {
                    "treatment_line": "First-line",
                    "patient_subgroup": "All patients",
                    "plan_name": "Corticosteroids",
                    "plan_details": "Hold immunotherapy; initiate prednisone 0.5-1 mg/kg/day or equivalent",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Recommended"
                }
            ]
        },
        {
            "staging_criteria": "Grade 3-4 (Severe/Life-threatening)",
            "risk_group": "High-risk (combination therapy, pre-existing autoimmunity)",
            "treatment_plans": [
                {
                    "treatment_line": "First-line",
                    "patient_subgroup": "All patients",
                    "plan_name": "High-dose corticosteroids",
                    "plan_details": "Permanently discontinue immunotherapy; methylprednisolone 1-2 mg/kg/day IV",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Recommended"
                },
                {
                    "treatment_line": "Refractory cases",
                    "patient_subgroup": "Colitis",
                    "plan_name": "Anti-TNFα/anti-integrin",
                    "plan_details": "Infliximab 5 mg/kg or vedolizumab if no improvement in 48-72 hours",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Recommended"
                },
                {
                    "treatment_line": "Refractory cases",
                    "patient_subgroup": "Hepatitis",
                    "plan_name": "Mycophenolate mofetil",
                    "plan_details": "1.5 g BID",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Recommended"
                },
                {
                    "treatment_line": "Refractory cases",
                    "patient_subgroup": "Neurologic irAEs",
                    "plan_name": "IVIG/Plasmapheresis",
                    "plan_details": "IVIG 2g/kg or plasmapheresis",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Recommended"
                },
                {
                    "treatment_line": "CAR T-specific",
                    "patient_subgroup": "CRS Grade 3-4",
                    "plan_name": "Tocilizumab + steroids",
                    "plan_details": "Tocilizumab 8 mg/kg IV + dexamethasone 10 mg q6h",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred"
                },
                {
                    "treatment_line": "CAR T-specific",
                    "patient_subgroup": "Refractory ICANS",
                    "plan_name": "Anakinra",
                    "plan_details": "IL-1R antagonist for steroid-refractory neurotoxicity",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Recommended"
                }
            ]
        },
        {
            "staging_criteria": "HLH/MAS syndrome",
            "risk_group": "CAR T-cell patients",
            "treatment_plans": [
                {
                    "treatment_line": "First-line",
                    "patient_subgroup": "Confirmed HLH",
                    "plan_name": "HLH-94 protocol",
                    "plan_details": "High-dose corticosteroids + etoposide",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Recommended"
                }
            ]
        }
    ],
    "biomarker_clinical_significance": {
        "clinical_significance": "Troponin/NT-proBNP: Early detection of myocarditis; IL-6/CRP/Ferritin: Correlate with CRS/HLH severity; Soluble CD25: Diagnostic for HLH/MAS; Autoantibodies (e.g., anti-AChR): Confirm autoimmune neurologic disorders; Neurofilament Light Chain: Marker for neuronal injury in ICANS; Cytokine profiles: Predict toxicity severity; CD4/CD8 ratio: Associated with CAR T-cell persistence and toxicity risk"
    },
    "guideline_id": "（2025.V1）NCCN临床实践指南：免疫治疗相关毒性的管理.txt"
}